Kazakhstan’s
pharmaceutical industry is demonstrating steady growth and strengthening the
position of domestic production. Today, more than 200 manufacturers are
registered in the country, and over 2,000 product items are supplied to the
market under long-term contracts. Investment is also providing momentum for the sector’s
development. Projects worth
more than 316 billion tenge are being implemented in the country with the launch of
new production facilities. Overall, last year the volume of pharmaceutical
output exceeded 190 billion tenge, showing positive dynamics. At the same time,
with the support of the government and relevant authorities, access to
medicines is improving. Price reductions have already been recorded for a
number of items - by an average of nearly a quarter. The
introduction of a single window principle and digital solutions is accelerating
medicine registration and making the market more transparent. This set of
measures is aimed at strengthening pharmaceutical security, developing the
domestic industry, and improving the quality of medical services. A key focus
is on expanding domestic production, attracting investment, and creating a
sustainable business environment. To this end, as industry representatives
note, the Government, on the instruction of the President, has developed a
comprehensive package of support measures for domestic producers, including
increasing the share of local manufacturers in the pharmaceutical market to 50
percent.
«We are creating a more predictable environment for major investors looking to build pharmaceutical manufacturing facilities here. Ultimately, these measures will increase the share of domestic producers in Kazakhstan’s market. In fact, this is not just about making medicines more affordable – it is also largely a matter of security. Ensuring access to medicines requires the development of domestic production, and significant work is already underway in this area,» noted Kanat Sharlapayev, Chairman of the Presidium, Atameken National Chamber of Entrepreneurs.
«The President’s state-of-the-nation
address highlighted the development of domestic producers to ensure the
country’s national security and achieve at least a 50 percent presence of
domestic pharmaceutical manufacturers in the market,» said Marina Durmanova, President of the Association for Support and
Development of Pharmaceutical Activities.
Related Articles
